daunorubicin has been researched along with amrubicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bungo, M; Fujiwara, Y; Fukuda, M; Horichi, N; Minato, K; Nakagawa, K; Niimi, S; Ohe, Y; Saijo, N; Sasaki, Y | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
2 other study(ies) available for daunorubicin and amrubicin
| Article | Year |
|---|---|
In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carubicin; Cisplatin; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Menogaril; Mitomycins; Nogalamycin; Tumor Cells, Cultured | 1989 |
Amrubicin induces apoptosis in human tumor cells mediated by the activation of caspase-3/7 preceding a loss of mitochondrial membrane potential.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 7; Cell Division; Daunorubicin; Drug Therapy, Combination; Enzyme Activation; Etoposide; G2 Phase; Humans; Membrane Potentials; Mitochondria; Tumor Cells, Cultured; U937 Cells | 2006 |